Skip to main content
Premium Trial:

Request an Annual Quote

Genera's Upcoming IPO Oversubscribed

NEW YORK (GenomeWeb News) – Australian molecular diagnostics developer Genera Biosystems said today that its upcoming initial public offering has closed oversubscribed, with demand for shares outweighing the number of shares offered.
 
The company expects its stock will begin trading on the Australian Stock Exchange under the ticker symbol GBI during the first week of June. Genera said it expects its market capitalization to be around AU $25 million ($24.1 million) when it begins trading.
 
Genera’s first product is the PapType, a test for human papillomavirus, and it also has another test for other sexually transmitted diseases in advanced pre-clinical development.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.